Expertise in
32
conditions

Dr. Allison C. Rosenthal

Hematology | Oncology
AZ - Cancer
5777 E Mayo Blvd, 
Phoenix, AZ 
Offers Telehealth
Expertise in
32
conditions
AZ - Cancer
5777 E Mayo Blvd, 
Phoenix, AZ 

Overview

Allison Rosenthal is a Hematologist and an Oncologist practicing medicine in Phoenix, Arizona.

Dr. Rosenthal is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 120 peer reviewed articles and participating in 7 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in AZ

Hospital Affiliations

Mayo Clinic Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

AZ - Cancer
5777 E Mayo Blvd, Phoenix, AZ 85054

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase I Study With an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sézary Syndrome (SS)
A Phase I Study With an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sézary Syndrome (SS)
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Duvelisib, Nivolumab
Study Phase: Phase 1
Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma
Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib, Pegfilgrastim, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 1
A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
Enrollment Status: Terminated
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: JBH492 Anti-CCR7 Antibody-Drug Conjugate
Study Phase: Phase 1
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 2
A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Biological, Drug
Study Drugs: Polatuzumab Vedotin, Rituximab, Hyaluronidase Human, Venetoclax
Study Phase: Phase 2
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Enrollment Status: Completed
Publish Date: November 27, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

120 Total Publications

Addressing the Self-Reported Needs of Adolescents and Young Adults With Cancer.
Addressing the Self-Reported Needs of Adolescents and Young Adults With Cancer.
Journal: Journal of adolescent and young adult oncology
Published: June 17, 2026
Similar Doctors
Expertise in
40
conditions
Dr. Craig B. Reeder
Hematology | Oncology
Expertise in
40
conditions
Dr. Craig B. Reeder
Hematology | Oncology
Referral may be required

Mayo Clinic Hospital In Arizona

5777 E Mayo Blvd, 
Phoenix, AZ 
 (0.1 miles away)
480-342-4800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Craig Reeder is a Hematologist and an Oncologist practicing medicine in Phoenix, Arizona. Dr. Reeder is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Waldenstrom Macroglobulinemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Reeder is currently accepting new patients.

Expertise in
22
conditions
Dr. Saurabh Chhabra
Hematology | Oncology
Expertise in
22
conditions
Dr. Saurabh Chhabra
Hematology | Oncology
Referral may be required

AZ - Cancer

5777 E Mayo Blvd, 
Phoenix, AZ 
 (0.1 miles away)
480-933-6836
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Saurabh Chhabra is a Hematologist and an Oncologist practicing medicine in Phoenix, Arizona. Dr. Chhabra is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Graft Versus Host Disease (GvHD), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Chhabra is currently accepting new patients.

Expertise in
20
conditions
Dr. Daniel H. Ahn
Hematology | Oncology
Expertise in
20
conditions
Dr. Daniel H. Ahn
Hematology | Oncology
Referral may be required

AZ - Cancer

5777 E Mayo Blvd, 
Phoenix, AZ 
 (0.1 miles away)
480-933-6836
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Ahn is a Hematologist and an Oncologist practicing medicine in Phoenix, Arizona. Dr. Ahn is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, and Neuroendocrine Tumor. Dr. Ahn is currently accepting new patients.

Frequently Asked Questions about Dr. Allison C. Rosenthal

How do I make an appointment with Dr. Allison C. Rosenthal?

You can book an appointment with Dr. Allison C. Rosenthal by calling their office at 480-933-6836. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Allison C. Rosenthal a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Allison C. Rosenthal is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Allison C. Rosenthal specialize in?

While Dr. Allison C. Rosenthal is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Allison C. Rosenthal participate in research or clinical trials?

Yes. Dr. Allison C. Rosenthal has published 120 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Allison C. Rosenthal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Allison C. Rosenthal accept my insurance?

Dr. Allison C. Rosenthal accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 480-933-6836 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rosenthal's expertise for a condition
ConditionClose
View All 18 Distinguished Conditions
View All 11 Advanced Conditions
View All 83 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile